Detection of the free acid of bimatoprost in aqueous humor samples from human eyes treated with bimatoprost before cataract surgery

被引:46
作者
Camras, CB
Toris, CB
Sjoquist, B
Milleson, M
Thorngren, JO
Hejkal, TW
Patel, N
Barnett, EM
Smolyak, R
Hasan, F
Hellman, C
Meza, JL
Wax, MB
Stjernschantz, J
机构
[1] Univ Nebraska, Med Ctr, Dept Ophthalmol, Omaha, NE 68198 USA
[2] Chemalys AB, Haninge, Sweden
[3] Univ Nebraska, Med Ctr, Dept Prevent & Societal Med, Omaha, NE USA
[4] Pfizer Ophthalm, New York, NY USA
[5] Univ Uppsala, Biomed Ctr, Dept Neurosci, Uppsala, Sweden
关键词
D O I
10.1016/j.ophtha.2004.06.028
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To determine whether bimatoprost is hydrolyzed to its free acid after topical application in humans in vivo. Design: Prospective, masked, and vehicle controlled. Participants: Thirty-one eyes of 31 patients with cataracts. Methods: Beginning 7 days before scheduled cataract surgery, one eye of each patient was treated with bimatoprost 0.03% or vehicle once daily, with the last drop administered 2 to 12 hours before anterior chamber paracentesis before cataract surgery. In a masked fashion, aqueous humor specimens were assayed for bimatoprost and its free acid by high-pressure liquid chromatography and mass spectrometry. Main Outcome Measure: Detection of the free acid of bimatoprost in aqueous humor. Results: Aqueous humor concentrations of the free acid of bimatoprost were 22.0+/-7.0 nmol/l (mean+/- standard error of the mean, n = 12) and 7.0+/-4.6 nmol/l (n = 8) at 2 and 12 hours, respectively, and below the limit of detection after vehicle (n = 10). Concentrations of bimatoprost (amide) were 5.7 11.4 and 1.1+/-0.4 nmol/l at 2 and 12 hours, respectively, and undetectable after vehicle. Conclusion: After topical application of bimatoprost in humans, a sufficient concentration of its free acid, a potent FP prostanoid receptor agonist, is found in the aqueous humor to account for its ability to reduce intraocular pressure. Ophthalmology 2004;111:2193-2198 (C) 2004 by the American Academy of Ophthalmology.
引用
收藏
页码:2193 / 2198
页数:6
相关论文
共 31 条
[1]   Comparison of once- or twice-daily bimatoprost with twice-daily timolol in patients with elevated IOP -: A 3-month clinical trial [J].
Brandt, JD ;
VanDenburgh, AM ;
Chen, K ;
Whitcup, SM .
OPHTHALMOLOGY, 2001, 108 (06) :1023-1031
[2]   Bimatoprost vs. timolol [J].
Camras, CB .
OPHTHALMOLOGY, 2002, 109 (04) :627-628
[3]   Bimatoprost: a member of a new class of agents, the prostamides, for glaucoma management [J].
Cantor, LB .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (04) :721-731
[4]   Hydrolysis of bimatoprost (Lumigan) to its free acid by ocular tissue in vitro [J].
Davies, SS ;
Ju, WK ;
Neufeld, AH ;
Abran, D ;
Chemtob, S ;
Roberts, LJ .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2003, 19 (01) :45-54
[5]   Bimatoprost and travoprost: A review of recent studies of two new glaucoma drugs [J].
Eisenberg, DL ;
Toris, CB ;
Camras, CB .
SURVEY OF OPHTHALMOLOGY, 2002, 47 :S105-S115
[6]   Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: I. Assessment of anti-inflammatory efficacy [J].
Gamache, DA ;
Graff, G ;
Brady, MT ;
Spellman, JM ;
Yanni, JM .
INFLAMMATION, 2000, 24 (04) :357-370
[7]   The hydrolysis of the prostaglandin analog prodrug bimatoprost to 17-phenyl-trinor PGF2α by human and rabbit ocular tissue [J].
Hellberg, MR ;
Ke, TL ;
Haggard, K ;
Klimko, PG ;
Dean, TR ;
Graff, G .
JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS, 2003, 19 (02) :97-103
[8]   3-oxa-15-cyclohexyl prostaglandin DP receptor agonists as topical antiglaucoma agents [J].
Hellberg, MR ;
Conrow, RE ;
Sharif, NA ;
McLaughlin, MA ;
Bishop, JE ;
Crider, JY ;
Dean, WD ;
DeWolf, KA ;
Pierce, DR ;
Sallee, VL ;
Selliah, RD ;
Severns, BS ;
Sproull, SJ ;
Williams, GW ;
Zinke, PW ;
Klimko, PG .
BIOORGANIC & MEDICINAL CHEMISTRY, 2002, 10 (06) :2031-2049
[9]   Identification and characterization of the ocular hypotensive efficacy of travoprost, a potent and selective FP prostaglandin receptor agonist, and AL-6598, a DP prostaglandin receptor agonist [J].
Hellberg, MR ;
McLaughlin, MA ;
Sharif, NA ;
DeSantis, L ;
Dean, TR ;
Kyba, EP ;
Bishop, JE ;
Klimko, PG ;
Zinke, PW ;
Selliah, RD ;
Barnes, G ;
DeFaller, J ;
Kothe, A ;
Landry, T ;
Sullivan, EK ;
Andrew, R ;
Davis, AA ;
Silver, L ;
Bergamini, MVW ;
Robertson, S ;
Weiner, AL ;
Sallee, VL .
SURVEY OF OPHTHALMOLOGY, 2002, 47 :S13-S33
[10]   Nepafenac, a unique nonsteroidal prodrug with potential utility in the treatment of trauma-induced ocular inflammation: II. In vitro bioactivation and permeation of external ocular barriers [J].
Ke, TL ;
Graff, G ;
Spellman, JM ;
Yanni, JM .
INFLAMMATION, 2000, 24 (04) :371-384